Seems like the true value generation after all is that more patients are going to the interventional suite for mechanical thrombectomy. Wondering how many other procedures have the potential to treat other disease states that are currently not being used to their maximum potential–Will Viz.ai capitalize on these other areas?

Quite fascinating to see the dynamics of cash and how it can mean so many different things for different hospitals. One aspect that I also envision will play a role in the future will be that companies like Viz gain access to amounts of data previously unheard of that can create sample sizes from such varied geographies. What are the ethical implications of using these data to potentially produce algorithms that put them astronomically ahead of any other competitor? And how will the data generators (individual hospitals, but even more patients and their families) be compensated for this competitive advantage?